Shots: The P-III PANORAMA trial involves assessing of Eylea (q8w, q16w) vs PBO (sham injection) in 402 patients with moderately-severe and severe NPDR for 52 weeks P-III PANORAMA trial results: […]readmore
Tags : Achieves
Shots: The P-III ARAMIS study involves assessing of Darolutamide (600mg bid) PO vs PBO in 1500 patients in ratio (2:1) with nmCRPC who are currently being treated with ADT The […]readmore
Shots: The two P-III study involves assessing of Dupixent + SOC vs PBO (nasal spray alone) in adults with CRSwNP & Dupixent + mometasone furoate nasal spray (MFNS) vs MFNS […]readmore
Shots: ASPECT-NP study (N=726) assessing ZERBAXA 3g IV (ceftolozane & tazobactam) vs. Meropenem 1g IV every eight hrs. for 8 to 14 days/ 14 days for Pseudomonas aeruginosa infection ASPECT-NP […]readmore